Skip to main content
. 2021 Jul 9;2(7):864–883.e9. doi: 10.1016/j.medj.2021.04.013

Figure 6.

Figure 6

Preventing the loss of gut barrier integrity decreases arthritis severity

(A) FITC-dextran concentration in the serum of untreated and AT-1001-treated C57BL/6 mice on day 3 of AIA (n = 10/group).

(B) Mean clinical score of untreated and AT-1001-treated mice following induction of AIA (n = 5/group).

(C) Mean percentage expression of splenic IFNγ+ and IL-17+ total CD45+ cells from untreated and AT-1001-treated arthritic mice (n = 5/group).

(D–G) Representative (D) H&E staining, (E) histological scores, (F) MUC2 staining, and (G) mean MUC2 intensity in the small intestines of untreated and AT-1001-treated arthritic mice (day 3 of AIA).

(H–J) Representative ZO-1 staining and mean ZO-1 intensity in SI and colon of naive mice and untreated and AT-1001-treated arthritic mice (day 3 of AIA).

(K) Mean percentage expression of LPAM-1+ and CCR9+ on total CD45+ splenocytes from untreated and AT-1001-treated arthritic mice (n = 5/group).

(L) Mean clinical score of arthritis in vehicle control and vercirnon-treated C57BL/6 mice (n = 5/group).

∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001. (A, C, and K) Unpaired t test, (G, I, and J) one-way ANOVA, and (B, E, and L) two-way ANOVA. For (A)–(K), one out of two experiments is shown. Data represent mean ± S.E.M.